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Abstract
Background: Arachidonic acid (AA) is a long-chain omega-6 polyunsaturated fatty acid (PUFA) synthesized from
the precursor dihomo-gamma-linolenic acid (DGLA) that plays a vital role in immunity and inflammation. Variants
in the Fatty Acid Desaturase (FADS) family of genes on chromosome 11q have been shown to play a role in PUFA
metabolism in populations of European and Asian ancestry; no work has been done in populations of African
ancestry to date.
Results: In this study, we report that African Americans have significantly higher circulating levels of plasma AA (p
= 1.35 × 10
-48) and lower DGLA levels (p = 9.80 × 10
-11) than European Americans. Tests for association in N = 329
individuals across 80 nucleotide polymorphisms (SNPs) in the Fatty Acid Desaturase (FADS) locus revealed
significant association with AA, DGLA and the AA/DGLA ratio, a measure of enzymatic efficiency, in both racial
groups (peak signal p = 2.85 × 10
-16 in African Americans, 2.68 × 10
-23 in European Americans). Ancestry-related
differences were observed at an upstream marker previously associated with AA levels (rs174537), wherein, 79-82%
of African Americans carry two copies of the G allele compared to only 42-45% of European Americans.
Importantly, the allelic effect of the G allele, which is associated with enhanced conversion of DGLA to AA, on
enzymatic efficiency was similar in both groups.
Conclusions: We conclude that the impact of FADS genetic variants on PUFA metabolism, specifically AA levels, is
likely more pronounced in African Americans due to the larger proportion of individuals carrying the genotype
associated with increased FADS1 enzymatic conversion of DGLA to AA.
Background
Levels of unsaturated fatty acids influence key cellular
functions necessary for life including the fluidity of
membranes, the function of membrane-associated pro-
teins, signal transduction events, the transcription of
proteins and the synthesis of lipid-derived bioactive
molecules. Seminal studies published in the 1930’sb y
Burr, Burr and Miller [1] demonstrated that the medium
chain unsaturated fatty acid (MC-PUFA), linoleic acid
(C18:2,ω6; LA), is essential for the survival and health of
rats. Later studies demonstrated that LA is ‘essential’
because it cannot be synthesized de novo in higher ani-
mals [2,3], and it is therefore indispensible in the synth-
esis of the long chain polyunsaturated fatty acids (LC-
PUFA), such as arachidonic acid (AA) [4].
The conversion of LA to AA occurs through the
actions of two desaturase (Δ6a n dΔ5) enzymes and an
elongase enzyme that introduce carbon-carbon double
bonds to and increase the chain length (2 carbons) of
LA, respectively. The Δ5a n dΔ6 desaturase enzymatic
steps have been recognized to be rate-limiting in AA
biosynthesis from LA [5]. In carnivores including
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products, specifically in organ and muscle meats and
egg yolks. Once formed or ingested from the diet, AA
impacts normal and patho-physiologic immune
responses through a variety of mechanisms including its
capacity to be converted to potent bioactive products
(such as prostaglandins, thromboxanes, leukotrienes and
lipoxins), to regulate and activate cellular receptors and
to impact the expression of genes that control immune
responses [6-8]. In humans, AA constitutes 5-10% of the
total fatty acids within inflammatory cellular lipids [9].
The Western diet has undergone a marked change
over the past 75 years [10]; in particular, the composi-
tion of fats in our diets has changed dramatically. The
consumption of LA has increased to an average of 15-20
g/day primarily derived from vegetable oils and margar-
ines. In fact, > 90% of total PUFAs in a typical Western
diet is LA. Until recently, biochemical studies using
stable isotope studies in subjects largely of European
ancestry have indicated only a small proportion of diet-
ary LA is converted to AA in humans suggesting that
even in the presence of high LA, there is limited capa-
city for it to be converted to AA [11-13]. The low rate
of conversion was assumed to apply to all human popu-
lations equally [5]. However, studies over the past five
years suggest genetic variability in the rate of conversion
of LA to AA [14-18]. Importantly, certain genetic var-
iants appear to be associated with higher levels of AA,
systemic inflammation and inflammatory disorders.
Marquardt et al reported the presence of three FA
desaturase (FADS) gene family members on chromo-
some 11q12-13 in humans that appeared to be necessary
for the synthesis of LC-PUFAs [19]. FADS1 and FADS2
were demonstrated to encode for Δ5 desaturase and Δ6
desaturase, respectively, and have been demonstrated to
be central in the conversion of LA to AA. FADS1-3,
potentially arising evolutionarily by gene duplication,
have a high degree of sequence identity (62-70%), almost
identical intron/exon organization [19] and appear to be
highly conserved between species (Additional File 1).
Numerous studies have examined the effects of genetic
variants in FADS1 and FADS2 in PUFA metabolism in
populations of European or Asian descent ({Malerba,
2008 #998;Xie, 2008 #999;Schaeffer, 2006 #1000;Rzehak,
2009 #1002;Bokor, #1004;de Antueno, 2001 #1005} and
reviewed in [20]). The strongest genome-wide associa-
tion (GWAS) signal associated with PUFA levels has
been the single nucleotide polymorphism (SNP)
rs174537 (p = 5.95 × 10
-46, [21]). This SNP accounts for
up to 19% of the variation in AA levels and maps to an
open reading frame (C11orf9) 14.4 kb upstream of
FADS1.
To date, few studies have examined the impact of
ancestry on LC-PUFA synthesis and levels. In 1991,
Horrobin and colleagues [22] measured AA levels in
plasma phospholipids of nineteen subjects from Zim-
b a b w eA f r i c aa n df o u n dt h e mt ob ea p p r o x i m a t e l y2 -
fold higher than a much larger group (N = 458) of sub-
jects with European ancestry. In the current study, we
measured levels of circulating ω6 PUFAs in African
Americans and European Americans in order to exam-
ine ancestry-related differences in PUFA metabolism
with respect to the FADS loci.
Results
Plasma fatty acid profiles differ in Americans of African
and European descent
Figure 1 shows the distribution of ω-6 PUFAs in the
African American and European American adults from
the GeneSTAR study. With the exception of DGLA, ω-6
PUFAs examined all appeared to be significantly higher
in the African Americans compared to European Ameri-
cans. There was an increase in the magnitude of the dif-
ference between the two racial groups as the length of
the carbon chain of the PUFAs increased (p-value for
LA = 0.001, for GLA = 1.37 × 10
-06, for DGLA = 9.80 ×
10
-11 and for AA = 1.35 × 10
-48). Furthermore, the ratio
of FADS1 product to precursor (AA/DGLA) was mark-
edly higher in the African American subjects (p = 2.06
×1 0
-38) suggesting a differential ability to convert
DGLA to AA through FADS1 pathway between the two
groups.
FADS SNP frequencies differ in Americans of African and
European descent
We compared allele frequencies between the African
Americans and European Americans in GeneSTAR for
seven of the most highly replicated FADS SNPs [16,21]
in the region of association with LC-PUFAs. The allele
associated with increased levels of LC-PUFAs was typi-
cally higher in frequency in the African Americans
(Table 1). For example at rs174537, the SNP with the
strongest published evidence for association with LC-
PUFAs, the frequency of the G allele was 91% in the
African Americans and only 67% in the European
Americans. These differences in allele frequency noted
in the GeneSTAR subjects were similarly observed in
the DHS study subjects and further replicated in the
publicly available data from the International HapMap
Project (http://www.hapmap.org) (Table 1).
To evaluate variation in the global distribution across
these loci, allele frequencies for SNPs in this chromo-
some region were subsequently examined in the publicly
available Human Genome Diversity Panel Data (http://
hgdp.uchicago.edu/cgi-bin/gbrowse/HGDP/). We found
the increased allele frequencies noted in the admixed
African ancestry populations (i.e. African Americans
from DHS and GeneSTAR, Table 1) to be more
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Page 2 of 10pronounced in the non-admixed populations within
Africa. Most noteworthy is the variation at rs174537,
where the derived allele (G) has swept to fixation (i.e.
100%) within the African continent, but is at intermedi-
ate frequencies in the European and Asian continents
and very minimally observed in Central America (Figure
2a). This translates to a 97.5% prevalence of the GG
genotype, the genotype associated with enhanced AA
levels in the African populations in the HGDP, as com-
pared to 50.6% in the European and 0% in the Central
American populations in the HGDP (Figure 2b).
Genotypic Effect of rs174537 on ω6 PUFAs and FADS1
enzymatic efficiency
Figure 3 and Table 2 summarize the distributions of
DGLA, AA, and AA/DGLA by genotype at rs174537
consistent with other published studies [16,21], and
show strong genotypic differences in trait means for
both racial groups (p = 2.23 × 10
-04 - 29.28 × 10
-23).
A ss h o w ni nF i g u r e3 ,t h ec o m m o na l l e l e( G )i sa s s o -
ciated with an increase in the mean plasma AA level
that is consistent with an additive model in both racial
groups. In contrast to AA, for DGLA the common
Figure 1 Population-based Differences in Plasma Fatty Acid Concentrations. Trait distribution differences between African American (N =
174) and European American (N = 155) individuals from the GeneSTAR study showing distributions in age- and gender-adjusted ω6 PUFAs (LA,
GLA, DGLA and AA) and FADS1 enzymatic efficiency (AA/DGLA). Each sample is represented by a single dot in blue for African Americans and
red for European Americans. Sample means and confidence interval for the sample mean are presented as the horizontal black line and
surrounding green box, respectively. Genes known to play a pivotal role in the desaturation and elongation step in the metabolism of AA are
illustrated. Individual PUFAs were expressed as percent of total fatty acids in a sample, and the ratio of AA mass/DGLA mass was calculated as a
measure of FADS1 enzymatic efficiency.
Table 1 Allelic Frequencies FADS Gene Cluster Variants Differ by Race
SNP Allele associated with
increased LC-PUFAS
GeneSTAR
a DHS
b HapMap
c
[ancestral/derived
allele]
d
Position African
American
European
American
African
American
European
American
CEU ASW YRI
rs174537 [T/G] 61309256 G 0.91 0.67 0.89 0.65 0.66 0.92 0.99
rs102275 [A/G] 61314379 A 0.37 0.67 0.33 0.64 0.65 0.39 0.31
rs174546 [T/C] 61326406 C 0.92 0.67 0.91 0.65 0.66 0.92 0.99
rs174556 [C/T] 61337211 C 0.92 0.71 0.91 0.68 0.7 0.93 0.99
rs1535 [G/A] 61354548 A 0.86 0.67 0.83 0.64 0.66 0.88 0.88
rs174576 [A/C] 61360086 C 0.74 0.66 0.7 0.64 0.66 0.71 0.72
rs174579 [C/T] 61362189 C 0.95 0.79 0.92 0.79 0.77 0.95 0.99
aAllele frequency estimates were obtained from in a defined set of all founders from the GeneSTAR families (339 African American founders and 484 European
American founders).
bFrequency based on 33 independent African American and 89 independent European American subjects from the DHS.
cData on the Utah residents with Northern and Western European ancestry from the CEPH collection (CEU), Yoruban in Ibadan, Nigeria (YRI) and African ancestry
in Southwestern USA (ASW) from the publicly available International HapMap Project (www.hapmap.org).
dDefinition of ancestral/derived allele based on dbSNP definitions (http://www.ncbi.nlm.nih.gov/projects/SNP/).
Frequencies of the allelic variant associated with higher levels of LC-PUFAs at seven SNPs mapping to the FADS gene cluster in the family-based GeneSTAR study,
subjects from the DHS study, and the publicly availably HapMap project, illustrating higher frequencies in individuals of African ancestry.
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Page 3 of 10allele (G) was associated with a decrease in mean levels
that is also consistent with an additive model in both
racial groups. For the ratio of AA/DGLA we observed
that the common allele (G) appears to be associated
with increased trait mean, i.e. increased enzymatic effi-
ciency. For each of the three traits, the estimate allelic
effect (i.e. b in Table 2) has highly overlapping confi-
dence intervals between the two racial groups indicat-
ing that the allelic effect on trait distribution is not
different between the two ancestry groups. Similar
results were noted across all significant SNPs from
Table 1 (see Additional File 2).
Figure 2 Geographic Differences in the Allelic Frequencies of a FADS Gene Cluster SNP. Geographic distribution (a) of derived allele
frequencies (shown in orange) for rs174537 in the 52 populations represented in the Human Genome Diversity Panel Data. The data suggest
the fixation of derived rs174537 G allele within the African continent. Similarly, the continental distribution for rs174537 genotypes (b) shows a
dramatic shift in the predominant homozygous state from Africa to the Americas.
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11q13 and ω6 PUFAs and FADS1 enzymatic activity
With the availability of genome-wide genotype data,
tests for association were performed across 80 SNPs in
a 184 kb region on 11q13 in the GeneSTAR subjects
stratifying on race. Association tests were performed for
DGLA, AA and AA/DGLA, the three traits found to be
most different between the two racial groups and that
appear to highlight FADS1 enzymatic activity as one
reason for this difference. Focusing on p-values < 10
-5
in Figure 4, the association signal in the African Ameri-
can subjects spanned a genomic region of 58 kb (blue
bracket) which was half of that observed in the Eur-
opean Americans (~121 kb, red bracket) and reflective
of smaller LD blocks and less inter-SNP correlation in
the African Americans. In the African Americans, we
observed a total of thirteen LD blocks, which included
60 out of the 80 total SNPs and these encompassed a
total 85.51 kb of the 184 kb region. In the European
Americans, we observed fewer (N = 10) LD blocks, but
these included more (N = 69) SNPs and encompassed a
larger region (121 kb).
T h ep e a ka s s o c i a t i o ns i g n a li nt h eA f r i c a nA m e r i c a n
sample from GeneSTAR for DGLA was p = 1.34 × 10
-10
(rs968567, explains 12% trait variation), for AA was p =
3.72 × 10
-5 (rs174537, explains 10% of trait variation),
and for AA/DGLA was p = 2.85 × 10
-16 (rs174534,
explains 15% trait variation). In the European American
group, maximum association signal noted was p = 7.84
×1 0
-5 (rs174549, rs174555, rs174556, explains 11% trait
Figure 3 Plasma Fatty Acid Concentrations Vary by Genotype at rs174537. Trait distribution differences between African Americans (N =
174) and European Americans (N = 155) participating in the GeneSTAR study, showing genotypic differences in according to DGLA, AA, and AA/
DGLA phenotype at marker rs174537 by race. Each sample is represented by a single dot in blue for African Americans and red for European
Americans. Sample means and confidence interval for the sample mean are presented as the horizontal black line and surrounding green box,
respectively.
Table 2 Allelic Effect on Trait Distribution in the Two
Ancestry Groups
PUFA Group p-value allelic effect b (95% CI)
DGLA African American 2.23 × 10
-04 0.225 (0.105,0.344)
European American 9.53 × 10
-05 0.162 (0.081,0.244)
AA African American 3.72 × 10
-05 -1.133 (-1.671,-0.594)
European American 9.28 × 10
-23 -1.461 (-1.754,-1.170)
AA/DGLA African American 6.07 × 10
-15 -1.483 (-1.855,-1.110)
European American 6.34 × 10
-19 -1.172 (-1.431,-0.914)
Allelic effect on trait distributions of age- and gender-adjusted ω6 PUFAs (AA
and DGLA) and FADS1 enzymatic efficiency (AA/DGLA) was examined in the
African Americans and European Americans from the GeneSTAR Study at
marker rs174537.
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Page 5 of 10variation) for DGLA, p = 2.68 × 10
-23 (also at rs174549,
rs174555, rs174556, explains 39% trait variation) for AA,
and 3.63 × 10
-19 (rs174568, explains 29% trait variation)
for AA/DGLA. With the exception of the signal at
DGLA (rs968567) in the African Americans, the stron-
gest signal in both groups was in the largest LD block
of each group, which includes all of the FADS1 gene.
Discussion
This is the first report comparing plasma levels of AA
and DGLA and genotypes at the FADS locus in African
Americans and European Americans. Our data suggest
that there are similar rates of conversion of the precur-
sor DGLA to its product AA among African Americans
and European Americans for each genotype at the lead
SNP rs174537 in the FADS locus. However, strong allele
frequency differences between the two groups, results in
a higher proportion of African Americans carrying the
genotypes known to be associated with higher levels of
AA and AA/DGLA, i.e. the GG genotype associated
with more efficient conversion of DGLA to AA.
Based on allele frequency estimates from the GeneS-
TAR and DHS studies, 79-82% of African Americans
carry two copies of the G allele while only 42-45% of
European Americans are GG. While it is possible that
African Americans consume higher quantities of pre-
formed AA itself, the most striking racial differences in
ω-6 PUFAs levels in these GeneSTAR data are with
DGLA, AA and AA/DGLA, a measure of FADS1 enzy-
matic activity. This coupled with the establishment of
identical FADS1 enzymatic efficiency (measured by AA
to DGLA ratios) with respect to key FADS genetic var-
iants plus the difference in proportion of population car-
rying the GG genotype, strongly suggest that part of the
striking phenotypic differences between the two racial
groups are genetic in origin.
Figure 4 Peak Association by Race. Tests for association for AA, DGLA and FADS1 enzymatic activity (AA/DGLA) in the ascertained sample
from GeneSTAR in African Americans and European Americans for 100 SNPs on chromosome 11q13. Strength of Association depicted as in the
legend, LD patterns (low to strong ranging from white to red) along with LD blocks (black triangles), and physical location of SNPs (blue lines)
relative to the three FADS genes (see insert).
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Page 6 of 10The GeneSTAR African American group appears to
confirm the association signal detected in European
Americans from previously published reports. However,
patterns of linkage disequilibrium are considerably dif-
ferent between the two racial groups, and what appears
to be a region extending over ~121 kb with association
p-values as strong as 10
-5 in the European Americans
appears less than half (~58 kb) that size in the African
Americans. The regions with peak signal in both groups
include rs174537, the peak GWAS SNP identified by
Tanaka et al [21], as well as rs968567, the SNP identi-
fied by Lattka et al [23] as a locus modulating the com-
plex regulation of FADS2 gene transcription. However,
the signal at rs968567 does not appear to be the peak
association signal in either racial group, with the excep-
tion of the DGLA phenotype in African Americans. Our
work focusing on FADS1 enzymatic efficiency suggests
that there may be other loci accounting for the associa-
tion signals in this region.
Conclusions
Given our observations of: (i) increased levels of AA in
African American subjects; (ii) a similar effect of geno-
type on FADS1 enzymatic efficiency in both racial
groups; and (iii) increased frequencies of alleles asso-
ciated with higher levels of AA in African Americans in
the FADS cluster, we surmise that African Americans
are genetically predisposed for more efficient conversion
of MC-PUFAs to LC-PUFAs. The pattern of allele fre-
quency in the FADS gene cluster between the African
American and European American subjects from both
the DHS and GeneSTAR data were also observed in the
HapMap samples, and were magnified when examined
across the full set of HGDP subjects. We noted a pat-
tern of allele frequency differences unique to the popu-
lations within the African continent across multiple
SNPs in this region (data not shown) and highlight that,
for a peak SNP in this region (rs174737), the allele that
is associated with increased AA levels is in fact fixed in
African populations, and within continental Africa,
97.5% of individuals carry the GG genotype based on
the HGDP.
There remains a disproportionate burden of preventa-
ble disease, death, and disability among racial and ethnic
minority populations, especially African Americans.
Observed racial and ethnic differences in prevalence
and/or severity of common diseases can only be
explained in part by environmental, social, cultural, or
economic factors, and genetic factors are likely at play
[24]. Differences in the prevalence and severity of
chronic diseases involving inflammation are further cor-
roborated by differences in inflammatory biomarkers
[25,26]. If the FADS locus does indeed account for as
much as 10% of the total phenotypic variation in plasma
AA levels in African Americans and as high as 39% in
European Americans, as seen in our study, then the
implications for a transition to a diet enriched in LA
and AA (i.e., a Western diet) and the consequent impact
on inflammation through AAs capacity to be converted
to potent bioactive products [6-8] might be quite signifi-
cant. Over 90% of PUFA consumed in the typical Wes-
tern diet is LA, and the dramatic increase in LA
consumption to 15-20 g/day that has occurred over the
past five decades in developed countries would be much
more likely to impact AA levels in populations of Afri-
can ancestry than European ancestry given the differ-
ences in genotype frequencies. We further conclude
from our work that the need to understand the genetics
of PUFA metabolism both at the FADS locus and else-
where in the genome is important. Humans of different
ancestry appear to exhibit differences in the rate of con-
version of LA to AA, and this may result in differences
in inflammatory contributions to chronic diseases as dis-
cussed above.
Methods
Study Populations
Genetic Study of Atherosclerosis Risk (GeneSTAR)
As previously described [27], the GeneSTAR study
included subjects from European American and African
American families identified through a proband with
documented coronary artery disease prior to 60 years of
age. Apparently healthy siblings of the probands, the
adult offspring of both the probands and their siblings,
and the coparents of the offspring were recruited
between 1998 and 2002. Genotype data were available
on all subjects from GeneSTAR, including 1,091 African
Americans and 1,625 European Americans from 306
and 467 families, respectively. The final selected sample
comprised African Americans (N = 174, 61% male;
mean age = 38.0 ± 12.2) from 98 families and European
Americans (N = 155, 32% male; mean age = 38.6 ±
12.1) from 126 families. Majority of the families were
singletons (N = 149) and 75 had two more individuals
(median = 2, range 2 - 8). The study protocol was
approved by the Johns Hopkins School of Medicine IRB,
and all subjects gave written informed consent.
Diabetes Heart Study (DHS)
There were 229 individuals from the Diabetes Heart
Study (DHS [28]) available for genotyping that included
European American (N = 166; from 89 families) and
African American (N = 63; from 33 families) subjects
with metabolic syndrome. Methods for ascertainment
and recruitment for the DHS have been described pre-
viously [28]. The Wake Forest University School of
Medicine Institutional Review Board (IRB) approved
study protocols, and all participants provided written
informed consent.
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Plasma was isolated from fasting whole blood samples
and fatty acid methyl esters (FAME) were prepared [29]
after saponification from duplicate samples (100 μl) in
the presence of an internal standard (triheptadecanoin)
as described in detail elsewhere [30]. A panel of 23 fatty
acids was quantified by gas chromatography with flame
ionization detection. Individual ω6 fatty acids (18:2ω6
linoleic acid = LA, 18:3ω6 gamma linoleic acid = GLA,
20:3ω6 dihomo-gamma linolenic acid = DGLA and
20:4ω6 arachidonic acid = AA) were expressed as per-
cent of total fatty acids in a sample, and the ratio of AA
mass/DGLA mass was calculated as a measure of
FADS1 enzymatic efficiency.
Genotyping and Analysis of Allele Frequencies
In GeneSTAR, genome-wide SNP genotyping was per-
formed at deCODE Genetics, Inc. using the Human
1Mv1_C array from Illumina, Inc. where 1,044,977 mar-
kers were released with an average call rate per sample
of 99.65% and an overall missing data rate of 0.35%.
From this panel, a total of 100 SNPs that mapped to a
184 kb region on chromsome 11q13, and encompassing
C11orf9, FADS1, FADS2 and FADS3 were available, and
a subset of 80 SNPs with a minor allele frequency
(MAF) > 5% in at least one of the two ethnic groups
was used in the final analyses. PLINK [31] was used to
detect and remove Mendelian errors. Hardy-Weinberg
equilibrium (HWE) and MAF for each SNP was tested
in a defined set of independent subjects (N = 319 Afri-
can American and 484 European American) represent-
ing the founders of the pedigrees. The highest deviation
from HWE was at a p-value of 0.0154, well above a
threshold of of 0.0006 (i.e. p = 0.05/number of SNPs
tested in each group).
In the DHS population, seven SNPs mapping to the
FADS gene cluster (rs174537, rs102275, rs174546,
rs174556, rs1535, rs174576, rs174579) were selected
based on previous publications [16,21]. Genotypes were
determined using a Sequenom Mass ARRAY SNP geno-
typing system (Sequenom Inc., San Diego, CA, USA)
[32]. Of the samples, 3.5% were genotyped in duplicate
with 100% reproducibility across the SNPs.
Statistical Analyses and tests for association
In the GeneSTAR population, the levels of five ω6f a t t y
acids (LA, GLA, DGLA, AA and AA/DGLA) were
adjusted for age and gender and analyzed to test for dif-
ferences between race and for an association with each
individual SNP within each racial group. Association
was performed under an additive model (i.e. a linear
r e c o d i n go ft h eS N Pa s0 / 1 / 2f o r0 ,1a n d2c o p i e so f
the minor allele) for AA, DGLA and AA/DGLA. Regres-
sion models were implemented in the generalized
estimating equation (GEE) framework with an exchange-
able covariance matrix to correct for familial correlation
[33]. Analyses were carried out using R (v.2.11.1) with
the gee package. Principal components-based estimates
of admixture were obtained using the smartpca program
in EIGENSOFT [34]. The first two eigenvectors in the
European Americans and the first eigenvector in African
Americans were included in the regression models.
Linkage disequilibrium (LD) was assessed by calculating
D’ and r
2 within Haploview [35], relying on a set of
independent individuals in the data. Haplotype blocks
were defined according to the algorithm of Gabriel et al
[36]. Tests for association were evaluated at a stringent
Bonferroni threshold of 0.0002 within each racial group
(i.e., a = 0.05/(80 SNPs * 3 traits)).
Additional material
Additional File 1: Conservation of FADS gene cluster presented as
percentage homology for protein and DNA between humans and
other species as reported in Homologene (http://www.ncbi.nlm.nih.
gov/homologene) revealing considerable conservation in range of
species including chicken for FADS1(~737%) and FADS2 (~75%),
and zebra fish for FADS2 (~65%).
Additional File 2: Allelic Effect on Trait Distribution in the Two
Ancestry Groups. Allelic effect on trait distributions of age- and
gender-adjusted ω6 PUFAs (AA and DGLA) and FADS1 enzymatic
efficiency (AA/DGLA) was examined in the African Americans and
European Americans from the GeneSTAR Study
Abbreviations
AA: arachidonic acid; DGLA: dihomo-gamma-linolenic acid; FADS: fatty acid
desaturase; FAME: fatty acid methyl ester; GEE: generalized estimating
equation; GLA: gamma-linolenic acid; GWAS: genome-wide association study;
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